Drugs / DELOCAMTEN
DELOCAMTEN
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07248839 | Dec 2025 → Aug 2026 overdue | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1 | NCT07226817 | Nov 2025 → Dec 2026 expected | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1 | NCT06577259 | Sep 2024 → Feb 2025 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT06476821 | Jun → Oct 2024 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05686096 | Jan → Apr 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05405543 | Jul → Nov 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05304533 | Apr → Nov 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06122779 | Nov 2023 → Dec 2026 expected | heart failure | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2 | NCT05556343 | Jan 2023 → Aug 2024 | — | Bristol-Myers Squibb | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DELOCAMTEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068426 ↗ |
| Known as | BMS-986435 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07226817 ↗ |
| Known as | MYK-224 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05405543 ↗ |
| Modality | Small molecule | — CHEMBL6068426 ↗ |
| Route | Oral | “single oral dose of BMS-986435” NCT06476821 ↗ |